$806.87
0.91% today
Nasdaq, Oct 14, 09:12 pm CET
ISIN
US04016X1019
Symbol
ARGX

argenx SE ADR Stock price

$799.56
+42.73 5.65% 1M
+193.17 31.86% 6M
+184.56 30.01% YTD
+256.00 47.10% 1Y
+448.79 127.94% 3Y
+524.33 190.51% 5Y
+776.56 3,376.35% 10Y
+776.56 3,376.35% 20Y
Nasdaq, Closing price Mon, Oct 13 2025
+2.64 0.33%
ISIN
US04016X1019
Symbol
ARGX
Industry

Key metrics

Basic
Market capitalization
$48.8b
Enterprise Value
$44.9b
Net debt
positive
Cash
$3.9b
Shares outstanding
61.2m
Valuation (TTM | estimate)
P/E
41.0 | 51.1
P/S
16.0 | 12.1
EV/Sales
14.7 | 11.1
EV/FCF
145.6
P/B
8.0
Financial Health
Equity Ratio
88.7%
Return on Equity
15.2%
ROCE
7.6%
ROIC
33.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.1b | $4.0b
EBITDA
$488.8m | $1.0b
EBIT
$466.6m | $1.0b
Net Income
$1.3b | $958.1m
Free Cash Flow
$308.7m
Growth (TTM | estimate)
Revenue
- | 84.8%
EBITDA
- | 22,503.4%
EBIT
- | 7,309.1%
Net Income
- | 15.0%
Free Cash Flow
194.9%
Margin (TTM | estimate)
Gross
89.4%
EBITDA
16.0% | 25.8%
EBIT
15.3%
Net
42.0% | 23.7%
Free Cash Flow
10.1%
More
EPS
$19.5
FCF per Share
$5.0
Short interest
3.0%
Employees
2k
Rev per Employee
$1.4m
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a argenx SE ADR forecast:

Buy
92%
Hold
8%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,051 3,051
-
100%
- Direct Costs 323 323
-
11%
2,728 2,728
-
89%
- Selling and Administrative Expenses 1,165 1,165
-
38%
- Research and Development Expense 1,170 1,170
-
38%
489 489
-
16%
- Depreciation and Amortization 22 22
91% 91%
1%
EBIT (Operating Income) EBIT 467 467
-
15%
Net Profit 1,280 1,280
-
42%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Neutral
GlobeNewsWire
11 days ago
October 3, 2025 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of shareholders will be held at 14:00 CET on Tuesday, November 18, 2025 at the offices of Freshfields LLP (Netherlands), Strawinskylaan 10, 1077 X...
Negative
Investors Business Daily
18 days ago
President Donald Trump delivered the pharmaceutical industry another blow this week, threatening 100% tariffs on some companies.
Neutral
Business Wire
26 days ago
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx SE, a global immunology company. As part of the expanded agreement, FUJIFILM Biotechnologies will initiate manufacturing of argenx' drug s...
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argenx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today